Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly C Fahnoe

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Plos One|December 15, 2012
Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in gram-negative pathogensKelly C Fahnoe, Mark E Flanagan, Glenn Gibson, et al.
Antimicrobial Agents and Chemotherapy|October 3, 2012
Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbamCraig J McPherson, Lisa M Aschenbrenner, Brian M Lacey, et al.
Frontiers in Immunology|July 7, 2025
C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patientsValeria Guaschino, Donata Santarsiero, Sara Gastoldi, et al.
Frontiers in Immunology|July 5, 2022
Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased TissueKelly C Fahnoe, Fei Liu, Jennifer G Morgan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 21, 2024
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementFei Liu, Sarah T Ryan, Kelly C Fahnoe, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Plos One|December 15, 2012
Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in gram-negative pathogensKelly C Fahnoe, Mark E Flanagan, Glenn Gibson, et al.
Antimicrobial Agents and Chemotherapy|October 3, 2012
Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbamCraig J McPherson, Lisa M Aschenbrenner, Brian M Lacey, et al.
Frontiers in Immunology|July 7, 2025
C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patientsValeria Guaschino, Donata Santarsiero, Sara Gastoldi, et al.
Frontiers in Immunology|July 5, 2022
Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased TissueKelly C Fahnoe, Fei Liu, Jennifer G Morgan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 21, 2024
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementFei Liu, Sarah T Ryan, Kelly C Fahnoe, et al.
Pageof 1